People living with serious or life-threatening diseases may seek access to investigational therapies outside of a clinical trial through a pathway known as expanded access (sometimes referred to as compassionate use).

VectorY is developing VTx-002 for people living with ALS. We recognize the urgent need for new treatment options for ALS and understand that some individuals and physicians may seek access to investigational therapies before they are approved. VTx-002 is an investigational therapy and has not been approved for marketing by any regulatory authority.  At this time, VectorY's priority is enrolling participants in and completing the ongoing Phase 1/2 VTx-002 PIONEER-ALS™ clinical trial (NCT07287397). This study is intended to help us better understand the safety, tolerability, dose, and potential effects of VTx-002 and provide information that will guide future studies. Accordingly, VTx-002 is currently available only through participation in the clinical trial, and VectorY is not accepting requests for expanded access at this time. Focusing our efforts on completing the VTx-002 clinical trial is the best way to support the continued development of VTx-002 for the ALS community.

Additional information about the VTx-002 PIONEER-ALS™ clinical trial is available at ClinicalTrials.gov.

VectorY reserves the right to revise this policy at any time in accordance with applicable laws and regulations, including the requirements of the U.S. 21st Century Cures Act.

VectorY commits to reviewing this policy at least every six months and may conduct an earlier review as clinically relevant new data emerge.

Last updated July 22, 2026